Randomized trial shows enzalutamide delays chemotherapy initiation in men with metastatic prostate cancer, indicating improved outcomes.
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).
No takes yet. Share an insight, caveat, or question.
Beer et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: